AstraZeneca/£AZN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About AstraZeneca
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
- Ticker
- £AZN
- Sector
- Health
- Primary listing
- LSE
- Employees
- 96,100
- Headquarters
- Cambridge, United Kingdom
- Website
- www.astrazeneca.com
AstraZeneca Metrics
BasicAdvanced
£206B
24.70
£5.39
0.16
£2.39
1.80%
Price and volume
Market cap
£206B
Beta
0.16
52-week high
£157.32
52-week low
£98.92
Average daily volume
2.6M
Dividend rate
£2.39
Financial strength
Current ratio
1.006
Quick ratio
0.785
Long term debt to equity
0.558
Total debt to equity
0.662
Dividend payout ratio (TTM)
43.82%
Interest coverage (TTM)
11.05%
Profitability
EBITDA (TTM)
16,234.086
Gross margin (TTM)
81.78%
Net profit margin (TTM)
17.68%
Operating margin (TTM)
25.80%
Effective tax rate (TTM)
17.04%
Revenue per employee (TTM)
£495,870
Management effectiveness
Return on assets (TTM)
8.58%
Return on equity (TTM)
22.57%
Valuation
Price to earnings (TTM)
24.695
Price to revenue (TTM)
4.332
Price to book
3.99
Price to tangible book (TTM)
-27.24
Price to free cash flow (TTM)
42.778
Free cash flow yield (TTM)
2.34%
Free cash flow per share (TTM)
3.109
Dividend yield (TTM)
1.80%
Growth
Revenue change (TTM)
7.32%
Earnings per share change (TTM)
17.30%
3-year revenue growth (CAGR)
11.51%
10-year revenue growth (CAGR)
10.11%
3-year earnings per share growth (CAGR)
23.15%
10-year earnings per share growth (CAGR)
13.74%
3-year dividend per share growth (CAGR)
3.66%
10-year dividend per share growth (CAGR)
1.44%
What the Analysts think about AstraZeneca
Analyst ratings (Buy, Hold, Sell) for AstraZeneca stock.
Analyst projections of the future price of AstraZeneca stock.
Bulls say / Bears say
In the first nine months of 2026, revenue rose 7% and core EPS rose 14%; AstraZeneca kept its full-year growth guidance. That shows it is still converting demand into earnings despite pressure on older medicines. (AstraZeneca)
Oncology, respiratory and immunology, and rare disease all delivered double-digit growth in the first nine months. Strength across several businesses makes growth less dependent on a single therapy area. (AstraZeneca)
AstraZeneca reported 12 positive Phase III readouts this year, with combined peak annual sales potential above $10 billion, and 47 approvals in major regions. These developments could supply new medicines to support growth beyond current launches. (AstraZeneca)
Farxiga and Brilinta are facing loss-of-exclusivity pressure, while China’s volume-based procurement scheme is also weighing on sales. AstraZeneca says growth in other areas is currently offsetting these headwinds, but they remain a drag on the portfolio. (AstraZeneca)
Recent trial setbacks expose the risk in relying on pipeline medicines for future growth: Etcamah missed its main goal in a late-stage breast-cancer trial, and AstraZeneca stopped a volrustomig lung-cancer trial after it was unlikely to meet its main goals. Further failures could weaken confidence in the pipeline. (Reuters, Reuters)
Higher investment and restructuring costs could weigh on cash generation: the company expects up to $2 billion in one-off restructuring costs, while net debt rose to $25.8 billion by the end of September. The planned savings may take time to offset those costs. (AstraZeneca, Proactive Investors)
Data summarised monthly by Lightyear AI. Last updated on 30 Oct 2026.
AstraZeneca Financial Performance
Revenues and expenses
AstraZeneca Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing AstraZeneca
AllEURGBPUSD
Fund name | Fund size | £AZN weighting |
|---|---|---|
iShares MSCI Europe Health Care Sector£ESIH | €940M | 14.04% |
iShares MSCI Europe Health Care Sector€ESIH | €940M | 14.04% |
iShares STOXX Europe 600 Health Care€EXV4 | €729M | 13.76% |
iShares Core FTSE 100£CUKX | £3.3B | 8.13% |
iShares Core FTSE 100£ISF | £16B | 8.13% |
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by London Stock Exchange, through Infront.